- Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials
- Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform
- TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program
- Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond
The San Diego-based pharmaceutical company,
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), has amply prepared for its Phase 2 clinical trials by leveraging high quality collaborations. For the Phase 2a studies, the company will work with the University of Michigan, the University of Florida, and Clinlogix, and to facilitate the advancement of TRP-8803 into Phase 2b clinical trials for chronic pain and eating disorders, respectfully. Tryp announced on July 7, a partnership with the University of Michigan as part of a series of upcoming bridging studies (
https://ibn.fm/r71NY).
A little over a month later, Tryp announced on August 10 new agreements with Calvert Labs, an Altasciences company and preclinical contact research organization (“CRO”), and Gad Consulting Services…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at
https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the
InvestorBrandNetwork.